Rationale Cognitive dysfunctions, including deficits in hippocampus-mediated learning and memory, are core features of the psychopathology of schizophrenia (SZ). Increased levels of kynurenic acid (KYNA), an astrocyte-derived tryptophan metabolite and antagonist of α7 nicotinic acetylcholine and N-methyl-D-aspartate receptors, have been implicated in these cognitive impairments. Objectives Following recent suggestive evidence, the present study was designed to narrow the critical time period for KYNA elevation to induce subsequent cognitive deficits. Methods KYNA levels were experimentally increased in rats (1) prenatally (embryonic day (ED) 15 to ED 22) or (2) during adolescence (postnatal day (PD) 42 to PD 49). The KYNA precursor kynurenine was added daily to wet mash fed to (1) dams (100 mg/day; control: ECon; kynurenine-treated: EKyn) or (2) adolescent rats (300 mg/kg/day; control: AdCon; kynurenine-treated: AdKyn). Upon termination of the treatment, all animals were fed normal chow until biochemical analysis and behavioral testing in adulthood. Results On the last day of continuous kynurenine treatment, forebrain KYNA levels were significantly elevated (EKyn + 472 %; AdKyn +470 %). KYNA levels remained increased in the hippocampus of adult EKyn animals (+54 %), but were unchanged in adult AdKyn rats. Prenatal, but not adolescent, kynurenine treatment caused significant impairments in two hippocampus-mediated behavioral tasks, passive avoidance and Morris water maze. Conclusions Collectively, these studies provide evidence that a continuous increase in brain KYNA levels during the late prenatal period, but not during adolescence, induces hippocampus-related cognitive dysfunctions later in life. Such increases may play a significant role in illnesses with known hippocampal pathophysiology, including SZ.
Introduction
Cognitive dysfunctions, including deficits in hippocampusmediated learning and memory, are a core domain of the psychopathology of schizophrenia (SZ). These impairments are associated with structural abnormalities and volumetric reductions of the hippocampus (Heckers et al. 1998; Steen et al. 2006) . This brain area is richly endowed with both Nmethyl-D-aspartate (NMDA) and α7 nicotinic acetylcholine (α7nACh) receptors from an early age (Ben-Ari et al. 1997; Dwyer et al. 2009) , and a considerable body of evidence suggests that abnormal neurotransmission at these receptors is causally related to the cognitive impairments in individuals with SZ (Timofeeva and Levin 2011) .
Kynurenic acid (KYNA), an endogenous neuroactive metabolite of the kynurenine pathway (KP) of tryptophan degradation, acts as an antagonist of both NMDA and α7nACh receptors. Elevated KYNA has been implicated in the pathology of SZ, as increased levels of both KYNA and its direct bioprecursor kynurenine, as well as disruptions in KP enzymes, have been documented in postmortem brain tissue and cerebrospinal fluid of individuals with SZ (Erhardt et al. 2001; Linderholm et al. 2012; Miller et al. 2006; Nilsson et al. 2005; Sathyasaikumar et al. 2011; Schwarcz et al. 2001) .
Excessive antagonism of NMDA and α7nACh receptors by KYNA in the brain may be especially related to the cognitive impairments seen in SZ. Thus, in animals, an acute elevation of brain KYNA induces cognitive dysfunctions reminiscent of those seen in patients with SZ. This includes deficits in pre-pulse inhibition of the acoustic startle reflex (Shepard et al. 2003) , sensorimotor gating (Erhardt et al. 2004) , working memory (Chess et al. 2007 ), contextual learning (Chess et al. 2009; Pocivavsek et al. 2011) , and cognitive flexibility (Alexander et al. 2012) . Additionally, in humans, polymorphisms in the gene of a pivotal KP enzyme, kynurenine 3-monooxygenase (KMO), have been associated with SZ (Aoyama et al. 2006; Holtze et al. 2011 ) and, specifically, with an impairment in smooth pursuit eye movement and visuospatial working memory ). Thus, both animal studies and genetic evidence in humans suggest a pathophysiologically significant association between KYNA and cognitive dysfunctions in SZ.
Epidemiological and neuropathological studies suggest that SZ is a neurodevelopmental disorder, wherein brain abnormalities are either inherited or sustained early in life, but not fully expressed until early adulthood (Murray and Lewis 1987; Weinberger 1987) . In fact, the clinical onset of SZ typically occurs after puberty, and the long latency between the presumed neurodevelopmental insult and the overt manifestation of the disorder later in life is a key feature of the disorder (Castle et al. 1998; DeLisi 2008; Kinney et al. 2010; Lieberman et al. 2001; Meyer and Feldon 2010) . Interestingly, the connection between KYNA and SZ may also have a developmental dimension. Thus, several of the perinatal risk factors associated with SZ, including stress and infections (Brown and Derkits 2010; Meyer and Feldon 2010; van Os and Selten 1998) , result in the activation of indoleamine 2,3-dioxygenase (IDO), a cytokine-responsive enzyme that catalyzes the formation of the key KP metabolite kynurenine (Kiank et al. 2010; Saito et al. 1991; Widner et al. 2000) . Kynurenine subsequently enters the brain from the circulation and is then irreversibly transaminated to KYNA. The formation of KYNA takes place preferentially in astrocytes, which release the metabolite into the extracellular milieu where it is ideally positioned to inhibit neuronal NMDA and α7nACh receptors and thus influence cognitive processes . Notably, KYNA concentrations in the mammalian brain are exceptionally high during the prenatal period (Beal et al. 1992; Ceresoli-Borroni and Schwarcz 2000) .
The current study is based on our recent demonstration that elevating brain KYNA from embryonic day (ED) 15 to postnatal day (PD) 21 results in impaired hippocampus-based learning and memory in the adult offspring (Pocivavsek et al. 2012) . In an effort to better define a critical developmental phase for this effect, we limited the experimental elevation of brain KYNA to the late prenatal period (ED 15 to 22), and compared this manipulation to an elevation of brain KYNA during the late adolescent period ("adolescence"), i.e., from PD 42 to 49. As in our previous studies (Alexander et al. 2013; Pocivavsek et al. 2012) , KYNA levels were increased by lacing rodent chow daily with kynurenine. Our results provide evidence that prenatal KYNA elevation alone is sufficient to induce behavioral dysfunctions later in life, and that essentially identical increases in brain KYNA during adolescence do not induce delayed deficits in hippocampus-mediated cognitive behaviors.
Materials and methods

Animals
Adult, pregnant Wistar rats (gestational age 2 days) were obtained from Charles River Laboratories for all embryonic kynurenine (EKyn) treatments. To normalize the size of the litters and to maximize the number of males, each litter was culled to ten pups on PD 2. Special attention was paid to assure that kynurenine administration did not disturb maternal behavior. Male offspring were used on ED 22, PD 2, or PD 56-85 (Fig. 1) . To minimize the contribution of individual litters, the average of 2-3 fetuses or pups per litter was considered as one subject in all biochemical experiments. For the behavioral experiments, subjects were the progeny from 7 litters per group, with no more than three pups from any given litter.
For adolescent kynurenine (AdKyn) treatment experiments, PD 35 male Wistar rats were obtained from Charles River Laboratories and pair-housed. Animals were tested experimentally on PD 49 and 70-85 (Fig. 1) .
All experimental animals were housed in a temperaturecontrolled facility, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, at the Maryland Psychiatric Research Center. The rats were kept on a 12/12 h light dark cycle and had free access to food and water. Experimental protocols followed the "Principles of Laboratory Animal Care" (NIH publication no. 86-23, 1996) and were approved by the institutional animal care and use committee of the University of Maryland School of Medicine.
Treatment
Rodent chow was ground finely in a food processor, and each dam or adolescent rat ate approximately 30 g per day. Rather than adjusting the amount of kynurenine administered to pregnant dams whose body weight rapidly increases during the last gestational week, a steady amount of kynurenine (100 mg) was administered for the EKyn treatment. This amount is equivalent to approximately 300 mg of kynurenine per kilogram body weight per day. Kynurenine was thoroughly mixed into the food daily for the kynurenine-treated dams, while controls received wet mash alone. Dams were fed the diet daily from ED 15 to 22. After giving birth, each dam received normal rodent chow pellets ad libitum. Male offspring were weaned on PD 21, pair-housed and given normal rodent chow pellets ad libitum. For AdKyn treatment, beginning on PD 42, 300 mg of kynurenine per kilogram body weight per day was thoroughly mixed into the food daily for kynurenine-treated animals, while controls received wet mash alone. Animals were fed the diet daily from PD 42 to 49. Upon completion of treatment, animals received normal rodent chow pellets ad libitum.
Chemicals
KYNA was purchased from Sigma (St. Louis, MO, USA). Lkynurenine sulfate ("kynurenine"; purity 99.4 %) was obtained from Sai Advantium (Hyderabad, India). Other chemicals were obtained from a variety of suppliers and were of the highest commercially available purity.
Chemical analyses
Kynurenine determination in serum Animals were euthanized using CO 2 , and whole trunk blood from dams and adolescent rats was collected in individual tubes containing 25 μl K 3 -EDTA (0.15 %) as an anticoagulant. Using the same anticoagulant, trunk blood, pooled from four fetuses per litter, was collected in (1.5 ml) Eppendorf tubes. The blood was gently centrifuged (300×g, 15 min) to separate serum and blood cells. The supernatant serum was transferred to new Eppendorf tubes, frozen on dry ice, and stored at −80°C. On the day of the assays, the samples were thawed, the serum was diluted 1:2, and 100 μl of diluted serum were acidified with 25 μl of 6 % perchloric acid. After centrifugation (12,000×g, 10 min), 20 μl of the supernatant were subjected to high-performance liquid chromatography (HPLC). Kynurenine was isocratically eluted from a 3-μm C 18 reverse-phase column (80 mm×4.6; ESA, Chelmsford, MA, USA), using a mobile phase containing 250 mM zinc acetate, 50 mM sodium acetate, and 3 % acetonitrile (pH adjusted to 6.2 with glacial acetic acid), using a flow rate of 1.0 ml/min. In the eluate, kynurenine was detected fluorimetrically (excitation 365 nm, emission 480 nm; PerkinElmer Series 200 fluorescence detector, Waltham, MA) at a retention time of approximately 6 min.
KYNA determination in tissue All animals were euthanized using CO 2 , followed by rapid removal of the brain. The forebrain (brain minus cerebellum and brainstem) (EKyn ED 22 and PD 2) or hippocampus (EKyn PD 56-85, AdKyn PD 49 and PD 70-85) were dissected out, rapidly frozen on dry ice, and stored at −80°C. On the day of the assays, tissues were thawed and sonicated in ultrapure water (1:5 w/v for PD 2 brains, 1:10 w/v for all other brains). One hundred microliter of the homogenate were acidified with 25 μl of 6 % perchloric acid. After centrifugation (12,000×g, 10 min), 20 μl of the supernatant were analyzed by HPLC as described above for kynurenine. In the eluate, KYNA was detected fluorimetrically (excitation 344 nm, emission 398 nm; PerkinElmer series 200) at a retention time of approximately 7 min.
Behavioral testing
An experimenter who was unaware of the treatment condition performed all behavioral experiments. Contextual memory The passive avoidance apparatus had two compartments of equal size (each 22-cm high, 18-cm wide, and 16-cm deep) separated by a guillotine door. One compartment was illuminated and the other remained dark. On the training day (acquisition trial), the animal was first placed in the illuminated compartment. The guillotine door was then opened, prompting the rat to naturally move quickly into the preferred dark compartment. The latency to enter the dark compartment was recorded as the "approach latency." After the door was closed, an inescapable foot shock (0.56 mA for 1 s) was delivered through metal rods of the floor. The retention of the newly formed aversive foot shock memory was tested 24 h later (retention trial). The rat was again placed in the light compartment, the guillotine door was opened, and the "avoidance latency", i.e., the time from opening the guillotine door to the time of entering the dark compartment, was recorded.
Spatial navigation and reference memory The Morris water maze (MWM) (pool dimension 180 cm in diameter) was used to study spatial navigation and reference memory as previously described (Morris 1984; Pocivavsek et al. 2012) . Briefly, each animal was habituated to the procedure and environment by navigating the opaque pool (nontoxic tempera paint) for 120 s, at least 24 h prior to training, to locate a hidden platform (10 cm in diameter, approximately 2 cm below water level). Then, each animal was trained for four trials, given up to 120 s to locate the hidden platform on each of six consecutive days. The intertrial interval was 120 s. The platform remained in the same hidden location across the 6 days of training. Rats were placed into the maze at different locations in a counterbalanced order across trials, days, and animals. On the seventh day, retention of the newly learned task and spatial navigation strategy were assessed in a single "probe trial," wherein the hidden platform was removed. Each animal was then given 120 s to navigate the pool, allowing the experimenter to examine retention and spatial navigation strategy. Immediately following the probe trial, each animal was tested again, with the platform made visible by a red flag and raised slightly above water level ("visible trial"). This latter trial was used to monitor visual acuity and general sensorimotor capabilities. Behavior during all trials was recorded by Noldus EthoVision tracking system (Leesburg, VA, USA).
Statistical analysis
For all biochemical analyses, comparisons were made using an unpaired Student's t test. Results from the passive avoidance paradigm were also analyzed using an unpaired Student's t test. MWM escape latency across days was analyzed using a two-way repeated measures analysis of variance (ANOVA) with treatment group as a between-subject factor and days as a within-subject factor. Post hoc analyses for the analysis of MWM latencies were performed using a Bonferroni t test correction with an adjusted alpha=P<0.008 per comparison. Swim speed, probe trial, and visual platform trial comparisons were made using an unpaired Student's t test. Statistical significance in the test was defined as P<0.05. All statistical analyses were performed using GraphPad Prism 5.0 software or SPSS 12.0 software.
Results
Kynurenine feeding increases serum kynurenine levels on the last day of treatment We first determined the effect of the kynurenine diet on serum kynurenine levels in both treatment paradigms. EKyn dams, control (ECon) dams, and their respective fetuses were killed on ED 22. At that time, kynurenine-treated dams had significantly higher levels of serum kynurenine compared to control dams (ECon 2.4±0.4 μM, n=6; EKyn 13.4±3.5 μM, n=7; P<0.05). Kynurenine levels in the serum of fetuses from kynurenine-treated dams were also significantly elevated compared to fetuses from control dams (ECon 3.3±0.4 μM, n= 5 litters; EKyn 16.4 ± 4.4 μM, n= 6 litters; P< 0.05) (Fig. 2a) . In contrast, on PD 2, kynurenine levels in the serum were no longer significantly different between pups from kynurenine-treated litters compared to control litters (ECon 2.3±0.1 μM, n=5 litters; EKyn 1.7±0.5 μM, n=4 litters; P= 0.43), suggesting that the elevation in fetal blood kynurenine levels on ED 22 had been dependent on the presence of the kynurenine in the dam's diet.
On PD 49, serum kynurenine levels in adolescent rats (AdKyn) that had been treated with kynurenine for 1 week were significantly elevated compared to control (AdCon) adolescent rats (AdCon 4.4±1.0 μM; AdKyn 23.4±3.6 μM, n=7 per group; P<0.001) (Fig. 2b) . Notably, the percent increase in serum kynurenine was not different in the EKyn offspring on ED 22 and in AdKyn animals on PD 49 (EKyn 397 %, AdKyn 432 %), indicating equivalence of the two treatment paradigms.
Brain KYNA levels are elevated with kynurenine treatment in both fetal (EKyn) and adolescent (AdKyn) animals Fetuses of kynurenine-treated dams showed substantial increases in KYNA levels in the brain. On ED 22, KYNA in the forebrain of fetuses from treated litters was significantly higher than in controls (ECon 1,344±233 fmol/mg protein, n=6 litters; EKyn 7,654±656 fmol/mg protein, n=7 litters; P<0.001) (Fig. 3a) . However, on PD 2, consistent with the serum kynurenine data, there was no difference between forebrain KYNA content in the offspring from treated litters compared to control litters (ECon 80.7±18.8 fmol/mg protein, n=5 litters; EKyn 107.0±22.5 fmol/mg protein, n=4 litters; P=0.40).
On the last day of AdKyn manipulation, i.e., PD 49, a significant elevation of hippocampal KYNA was seen in kynurenine-treated animals compared to controls (AdCon 75.9±20.6 fmol/mg protein; AdKyn 442.7±44.4 fmol/mg protein, n=7 per group; P<0.001) (Fig. 3b) . Thus, brain KYNA levels were similarly elevated after kynurenine treatments at both ages (EKyn 470 %, AdKyn 482 %), again confirming equivalence of the two experimental protocols in raising KYNA levels.
Prenatal, but not adolescent, kynurenine treatment increases KYNA in the adult rat brain After treatment was terminated on either ED 22 (EKyn) or PD 49 (AdKyn), all rats received normal rodent chow until the completion of the study. When the animals reached adulthood and were at least 3 weeks off kynurenine treatment (EKyn PD 56-85; AdKyn PD 70-85), the levels of KYNA were assessed in the hippocampus. KYNA levels were significantly higher in EKyn (104.1±23.5 fmol/mg protein, n=4 litters) than in ECon (47.4±3.5 fmol/mg protein, n=6 litters; P<0.05) rats (Fig. 4a) . In contrast, there was no difference in KYNA levels in the hippocampus of rats treated with kynurenine or regular chow during the adolescent period (AdCon 59.7±8.6 fmol/mg protein; AdKyn 51.5±4.8 fmol/mg protein, n=8 per group; P=0.42) (Fig. 4b) .
Deficits in hippocampal learning and memory in adult EKyn, but not AdKyn, animals Next, we investigated the impact of continuous prenatal or adolescent kynurenine treatment on performance in two hippocampus-mediated behaviors, i.e., contextual memory in the passive avoidance paradigm, and spatial learning and memory in the MWM. Adult animals were examined on both tasks in a counterbalanced order, with at least 4 days between tasks. On the first day of passive avoidance testing, the acquisition trial, rats from control and kynurenine-treated groups did not differ significantly in approach latencies (ECon 19.5± 3.3 s; EKyn 22.9±4.6 s, n=15 each, 7 litters represented in both groups; P=0.58) (AdCon 19.3±3.1 s; AdKyn 25.9± 4.6 s, n=15 per group; P=0.25) (Fig. 5a, b) . When tested 24 h later in the retention trial, the avoidance latencies of animals treated prenatally with kynurenine were significantly shorter than those of control animals (ECon 138.2±22.5 s; EKyn 63.6±18.4 s; P<0.05) (Fig. 5c ). However, there was no difference in the avoidance latencies of animals receiving kynurenine during adolescence and their respective controls (AdCon 150.7 ± 28.7 s; AdKyn 152.6 ± 30.2 s; P= 0.96) (Fig. 5d) .
When tested in the MWM, adult rats treated prenatally with kynurenine showed an overall significant effect on escape latency compared to controls (F 1,28 =10.16, P<0.01). There was no significant interaction between treatment and escape latency across days (F 5,140 =1.71, P=0.135). A series of oneway ANOVAs comparing escape latency of ECon versus EKyn on each day revealed that the two groups differed significantly on day 2 (P<0.008) (n=15 each, 7 litters represented in both groups) (Fig. 6a) . These data demonstrated that kynurenine treatment during a sensitive period of prenatal development slows the rate of acquisition in the spatial learning task in adulthood. In contrast, adult rats that were treated with kynurenine during adolescence showed no difference in escape latency across days compared to controls (F 1,19 =0.18, P=0.69) (AdCon, n=10; AdKyn, n=11), suggesting no deficit in learning the task (Fig. 6b) .
Retention of the newly learned task and spatial navigation strategy were assessed in one single probe trial 24 h after the last training session. Animals treated prenatally with kynurenine crossed into the area formerly occupied by the platform less frequently than control animals (ECon 5.2±0.6 crosses; EKyn 2.8±0.7 crosses; P<0.05) (Fig. 6c) , whereas no such difference was seen between animals treated with kynurenine during adolescence and their respective controls (Fig. 6d) . Moreover, swim speeds did not differ significantly between the comparable groups (ECon 30.3±1.0 cm/s; EKyn 32.6±0.8 cm/s; P=0.09; AdCon 38.9±1.9 cm/s, AdCon 40.2 ±2.1 cm/s; P=0.65) during the probe trial. Finally, a visible trial was conducted immediately after the probe trial. There were no differences in the escape latencies between each of the two experimental groups (ECon 15.0±6.0 s; EKyn 20.4± 3.5 s; P=0.47; AdCon 14.7±3.2 s; AdKyn 16.4±3.4 s; P= 0.73), indicating that kynurenine treatment, either prenatally or during adolescence, did not cause gross visual deficits later in life. 
Discussion
The present study explored and compared the effects of continuous prenatal (EKyn) and adolescent (AdKyn) exposure to kynurenine on brain KYNA levels and on delayed hippocampus-dependent learning and memory in rats. First, we confirmed that the lacing of chow with kynurenine resulted in elevated brain KYNA levels on the last day of treatment in Fig. 5 Only animals exposed to kynurenine during the prenatal period (EKyn) show contextual memory impairment in adulthood. Prenatal treated rats were exposed to kynurenine (100 mg/day; EKyn) from ED 15 to 22 and adolescent treated rats were exposed to kynurenine (300 mg/kg/day; AdKyn) from PD 42 to 49. Adult animals were tested in the passive avoidance paradigm (EKyn PD 56-85; AdKyn PD 70-85; n=15 per group). No differences in approach latency were observed on the training day for both EKyn (a) and AdKyn (b) animals compared to respective controls (ECon or AdCon). Avoidance latency differed significantly between the EKyn and ECon group (c), but did not differ between the AdKyn and AdCon group (d). All data are the mean±SEM. **P<0.01 versus control (ECon) Fig. 6 Spatial learning and reference memory is only impaired in animals receiving kynurenine during the prenatal period (EKyn). Prenatal treated rats were exposed to kynurenine (100 mg/day; EKyn) from ED 15 to 22, and adolescent treated rats were exposed to kynurenine (300 mg/kg/day; AdKyn) from PD 42 to 49. Animals were tested in the MWM during adulthood (EKyn PD 56-85; AdKyn PD 70-85). a, b Test across 6 days of training; c, d number of platform crossings during the probe trial (video tracking analysis). All data are the mean. (ECon n=15; EKyn n=15) (AdCon n=10; AdKyn n=11) *P<0.05 versus control (ECon) both groups. Notably, the magnitude of this biotransformation was quantitatively similar in EKyn and AdKyn rats. Upon completion of treatment, both EKyn and AdKyn animals received normal non-laced chow until biochemical and behavioral testing in adulthood, a period defined as either PD 56 or later (EKyn) or at least 3 weeks after the last day of treatment (AdKyn). In adulthood, animals that had received kynurenine during the prenatal period displayed a significant increase in hippocampal KYNA when compared to respective controls, but no such difference was seen in adult AdKyn rats.
In separate animals, we investigated the performance in two hippocampus-dependent behavioral tasks, the passive avoidance paradigm and the MWM test. Adult EKyn rats, which showed increased KYNA levels in the brain, displayed abnormalities in both tasks, signifying dysfunction of learning and memory. In contrast, adult AdKyn animals, which have normal brain KYNA, were not impaired. These findings indicate that prenatal exposure to kynurenine, leading to longlasting elevations in brain KYNA levels, is sufficient to cause biochemical and behavioral effects in adulthood, whereas the same treatment during adolescence does not produce these enduring changes.
The present set of experiments was based on our previous studies, where dams were continuously treated with kynurenine from ED 15 to PD 21, and where brain KYNA levels in the offspring remained chronically elevated until weaning (Alexander et al. 2013; Pocivavsek et al. 2012) . Here, we showed that a rise in brain KYNA levels during a relatively narrow embryonic period alone, i.e., from ED 15 to 22, was sufficient to induce biochemical and behavioral abnormalities in adulthood. These results complement several reports on long-lasting behavioral impairments following various experimental manipulations during the last week of prenatal development (Kapoor et al. 2009; Koenig et al. 2005; Lodge and Grace, 2009; Meyer 2014; Meyer and Feldon 2010) . While several of the insults used in these studies, including stress or immune activation, increase the formation of KP metabolites as a consequence of IDO activation Miura et al. 2011; Raison et al. 2010; Widner et al. 2000) , the present study demonstrates more directly that a prenatal increase in brain KYNA is associated with longlasting biochemical and behavioral abnormalities. In line with the concept of "early-life priming of adult diseases" (Bale et al. 2010) , we therefore suggest that exposure of the brain to abnormally elevated amounts of KYNA during a critical period of prenatal development disrupts normal brain maturation and subsequently curtails the ability of the adult brain to learn novel tasks and form contextual memories (as assessed by MWM and passive avoidance). Notably, these results and conclusions are in excellent agreement with a recent series of experiments by Stone and collaborators, who used a pharmacological approach, namely systemic application of the specific KMO inhibitor Ro 61-8048 (Röver et al. 1997) , to raise brain kynurenine and KYNA levels during the late gestational period. In these studies, repeated prenatal administration of Ro 61-8048 led to long-lasting deficits in long-term potentiation, measured in the CA1 region of hippocampal slices generated from adult offspring (PD 60), and was associated with a significant decrease in the expression of GluN2A glutamate receptors (Forrest et al. 2013a, b) .
In recent years, the effects of early postnatal or adolescent KP manipulations on behavioral performance in adult animals have been explored in several laboratories. This included intermittent systemic kynurenine injections between PD 27 and 53, and behavioral testing on PD 61 (Akagbosu et al. 2012; Trecartin and Bucci 2011) , repeated kynurenine injections on PD 7-16 ) or 7-10 (Iaccarino et al. 2013 ) with testing in adulthood, and our own perinatal kynurenine administration paradigm (Alexander et al. 2013; Pocivavsek et al. 2012) . In all these studies, as well as after transient elevation of brain KYNA levels following early postnatal viral infection , adult animals exhibited impairments in a variety of cognitive or social behaviors.
In the present study, we failed to demonstrate long-term effects of a 1-week exposure to kynurenine when the animals were treated during the adolescent period (AdKyn rats, PD 42 to 49). Potential explanations for the contrasting positive findings of Akagbosu et al. (2012) and Trecartin and Bucci (2011) may be related to the respective treatment paradigms (intermittent vs. continuous application of kynurenine), the mode and dose of kynurenine administration (100 mg/kg given i.p. vs. 300 mg/kg laced into daily chow), the amount of time elapsed between the final exposure to kynurenine and behavioral testing (8 vs. 21 days), the behavioral tests selected, and the age of the animals when the treatment was initiated (PD 27 vs. 42). Elucidation of these differences will likely provide important insights regarding the mechanism(s) linking early KP abnormalities to delayed behavioral deficits.
Two preferential targets of endogenous KYNA, NMDA, and α7nACh receptors (Albuquerque and Schwarcz 2013; Moroni et al. 2012; Stone et al. 2013 ) play central roles in brain maturation in the perinatal period by participating in neuronal migration, cellular integration, and hippocampal neurogenesis (Hensch 2005; Huntley et al. 1994; Lozada et al. 2012; Russo and Taly 2012; Ultanir et al. 2007 ). It therefore seems reasonable to speculate that a prenatal elevation in KYNA levels, which will increase inhibition of both of these receptors, may have an adverse impact on developmental processes. This effect may be especially pronounced in the hippocampus, which is richly endowed with both receptors from an early stage in development (Ben-Ari et al. 1997; Dwyer et al. 2009; Falk et al. 2002; Jantzie et al. 2014 ). In addition, as both α7nACh and NMDA receptors are critically involved in learning and memory formation throughout life (Levin et al. 2006; Robbins and Murphy 2006) , excessive inhibition of these receptors by elevated hippocampal KYNA levels (cf. Fig. 4a ) may also be causally related to the behavioral deficits shown here in adult EKyn rats. Conversely, the normal KYNA levels in the brain of adult AdKyn rats (Fig. 4b ) may explain why these animals performed normally in tests of contextual memory, and spatial learning and memory.
In adult rodents, elevation of brain KYNA causes a prompt reduction in extracellular glutamate levels in several regions including the hippocampus (Carpenedo et al. 2001; Pocivavsek et al. 2011; Wu et al. 2010) . This effect, which appears to be mediated by inhibition of glutamate release via presynaptic α7nACh receptors (Alexander et al. 2012) , has been proposed to be causally related to the array of cognitive and other behavioral changes that are observed when kynurenine or KYNA are applied acutely to adult animals (Alexander et al. 2012; Chess et al. 2007 Chess et al. , 2009 Erhardt et al. 2004; Pocivavsek et al. 2011; Shepard et al. 2003) . As several of these effects resemble phenomena that are observed in individuals with SZ, and as KYNA levels are elevated in brain and cerebrospinal fluid of patients (Erhardt et al. 2001; Schwarcz et al. 2001) , KYNA may play a pathophysiologically significant part in the disease (cf. Introduction). The present demonstration of relevant long-term effects in EKyn, but not AdKyn, rats suggests that experimental KYNA elevation during a sensitive period of prenatal development can be used to examine the role of KP dysfunction in the etiology of SZ.
Ongoing studies in our laboratories use the new experimental paradigm to test adult EKyn rats for additional neurochemical, structural, and behavioral abnormalities Pershing et al. 2013) and to study the trajectory of molecular and cellular changes that must occur in the brain of EKyn animals between birth and adulthood. We are especially intrigued by the mechanism(s) underlying the elevation in hippocampal KYNA levels in adult EKyn rats. This increase is also seen in the prefrontal cortex and, though less pronounced and so far only observed in microdialysis samples, in animals that are continuously treated with kynurenine between GD15 and PD21 (Pocivavsek et al. 2012) . Preliminary studies indicate that this second surge in KYNA levels may be causally related to a delayed reduction in cerebral KMO activity, which is seen in adult EKyn, but not in adult AdKyn, rats .
Finally, we are also attempting to prevent the early accumulation of KYNA in the brain by administering kynurenine together with BFF-816, which is orally available and selectively inhibits kynurenine aminotransferase II, the major biosynthetic enzyme of KYNA in the rat brain (Guidetti et al. 2007; Wu et al. 2014) . Together, these and complementary studies may have significant translational value for the treatment of SZ and other psychiatric disorders Wonodi and Schwarcz 2010) .
